PSK23 Feb 2011 19:03
Singer Capital Markets issued a "buy" rating for ProStrakan (PSK), the international specialty pharmaceutical company, with a 135p target price. The broker notes yesterday's announcement that the Canadian regulators have approved breakthrough cancer pain therapy Abstral and, as an exclusive supplier, the group will receive manufacturing fees together with a number of small, undisclosed, sales related milestones. Singer also notes Norgine's increased holding in the company, and, although the probability of a potential counter-bid is not necessarily high, advises investors to await further developments. ProStrakan shares edged down 0.25p to 132.75p.